Genzyme Corporation, with their major pharmaceutical manufacturing and distribution located in Haverhill, is one of the most successful and influential biotechnology companies in the world.

The company are currently investing £55M at the Haverhill site to increase capacity for their new potential 'blockbuster' drug, Renagel; used for the control of Phosphate in kidney dialysis patients. The investment in Haverhill reflects Genzyme's ongoing commitment to the area, with its innovative and dedicated workforce, space to expand, and good housing and amenities for all employees.